Loading...
Back to narrative

531335: Profitability Is Expected To Improve Following Upcoming Board Results Review

Steady Expansion And Dividend Outlook Will Support Future Shareholder Value

531335 logo
531335
AnalystConsensusTarget
Not Invested
Published 10 Feb 2025

Update shared on 11 Dec 2025

Previous
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
6.3%
7D
4.8%

Analysts have nudged their price target on Zydus Wellness to ₹530.91 per share, a modest revision that reflects largely unchanged assumptions on long term revenue growth, profitability and valuation multiples.

What's in the News

  • Board meeting scheduled for November 5, 2025 at 11:15 IST to review and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing)
  • Limited review reports from Mukesh M. Shah & Co., Chartered Accountants, and the statutory auditors will be considered alongside the September 30, 2025 financial results, in line with Regulation 33 of the Listing Regulations (company filing)
  • Regulatory compliance focus highlighted by the formal board consideration of both results and the auditor review for the September 2025 period, underscoring governance and disclosure standards (company filing)

Valuation Changes

  • Fair Value: Unchanged at approximately ₹530.91 per share, indicating no material reassessment of intrinsic value.
  • Discount Rate: Stable at about 12.76 percent, reflecting no change in the risk and return assumptions applied to future cash flows.
  • Revenue Growth: Effectively flat at around 27.85 percent, with only rounding-level adjustments that do not alter the growth outlook.
  • Net Profit Margin: Steady at roughly 10.01 percent, with negligible numerical refinements that leave margin expectations intact.
  • Future P/E: Unchanged at close to 40.47x, suggesting valuation multiples and earnings expectations remain consistent with prior estimates.

Have other thoughts on Zydus Wellness?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.